In addition, 13 Greenfield Manufacturing Plants for Medical Devices under the PLI Scheme were inaugurated in New Delhi. 

The PLI scheme is a result of wide-ranging deliberations on India’s dependence on critical resources, risk to supply chain bottlenecks and the Industry’s global competitiveness, said Dr Mansukh Mandaviya on Saturday.

“It is noteworthy that today India has not only reduced its dependence on medicines, API and medical devices, the country is also emerging as a major exporter of these products, thanks to the success of the PLI scheme”.

“Soon Penicillin G will be made in India. Since last 30 years, not being produced in India. Now under Atmanirbhar Bharat, we will produce it in the country itself”.

Notable points are : 

*PLI scheme envisages manufacturing of 41 Bulk. 

*Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30

*26 Applicants for manufacturing of Medical Devices have been approved for 138 products under the PLI scheme with total financial outlay of Rs.3,420 cr. for the period 2020-21 to 2027-28.